Fused pyrazoles as FGFR inhibitors

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

W is N or CR 6 ;

Y is N or CR 7 ;

Z is N or CR 8 ;

wherein one or two of W, Y, and Z is N;

L is absent or selected from C 2-6 alkenylene, C 3-6 heteroalkenylene, C 2-6 alkynylene, and C 3-6 heteroalkynylene, wherein said C 2-6 alkenylene, C 3-6 heteroalkenylene, C 2-6 alkynylene, and C 3-6 heteroalkynylene are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , ORB, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)OR a , NR c C(O)NR c R d , C(═NR e )R b , C(═NR e )NR c R d , NR c C(═NR e )NR c R d , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , S(O)R b , S(O)NR c R d , S(O) 2 R b , and S(O) 2 NR c R d ;

A is selected from Formulas [aa], [bb], and [cc]:

rings B and C in Formula [aa] together form a fused bicyclic heterocycle, wherein ring B is a six-membered aromatic ring selected from phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and triazinyl, wherein ring C is a 5- or 6-membered carbocycle or a 5- or 6-membered heterocycle, wherein 0, 1, or 2 ring-forming carbon or nitrogen atoms in ring C can be substituted by oxo, and wherein the fused bicyclic heterocycle comprising rings B and C is attached to L in Formula I via a ring atom in ring B;

Q 1 , Q 2 , and Q 3 are each independently selected from N and CH, wherein at least one of Q 1 , Q 2 , and Q 3 is CH;

each R X is a substituent on ring B and is independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 cyanoalkyl;

each R Y is a substituent on ring C and is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, Cy 1 , OR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , C(═NR e1 )R b1 , C(═NR e1 )NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , and S(O) 2 NR c1 R d1 , wherein said C 1-6 alkyl, is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R Ya ;

each R Ya is independently selected from Cy 1 , halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , C(═NR e1 )NR c1 R d1 , NR c1 C(═NR e1 )NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , NR c1 C(O)NR c1 R d1 , NR c1 S(O)R b1 , NR c1 S(O)R b1 , NR c1 S(O) 2 NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , and S(O) 2 NR c1 R d1 , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R Ya are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 1 , halo, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , C(═NR e1 )NR c1 R d1 , NR c1 C(═NR e1 )NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , NR c1 C(O)NR c1 R d1 , NR c1 S(O)R b1 , NR c1 S(O) 2 R b1 , NR c1 S(O) 2 NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , and S(O) 2 NR c1 R di ;

each R A is independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Cy 2 , CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , C(═NR e2 )R b2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ; wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R AZ ;

each R AZ is independently selected from Cy 2 , halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R AZ are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 2 , halo, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

R B1 is H, C 1-6 alkyl, Cy 3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , C(═NR e3 )R b3 , or C(═NR e3 )NR c3 R d3 ; wherein said C 1-6 alkyl, is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R BZ ;

each R BZ is independently selected from Cy 3 , halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , and S(O) 2 NR c3 R d3 , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R BZ are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy 3 , halo, CN, NO 2 , OR a3 , SR a2 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , and S(O) 2 NR c3 R d3 ;

each R B2 is independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Cy 3 , CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , C(═NR e3 )R b3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , and S(O) 2 NR c3 R d3 ; wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R BZ ;

R 1 , R 2 , R 4 , and R 5 are each independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, CN, OR a4 , SR a4 , C(O)NR c4 R d4 , N c4 R d4 , NR c4 C(O)R b4 , NR c4 S(O)R b4 , NR c4 S(O) 2 R b4 , S(O)R b4 , S(O)N c4 R d4 , S(O) 2 R b4 , and S(O) 2 N c4 R d4 ; wherein said C 1-4 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OR a4 , SR a4 , C(O)NR c4 R d4 , N c4 R d4 , NR c4 C(O)R b4 , NR c4 S(O)R b4 , NR c4 S(O) 2 R b4 , S(O)R b4 , S(O)N c4 R d4 , S(O) 2 R b4 , and S(O) 2 NR c4 R d4 ;

R 3 is H, halo, C 1-4 alkyl, C 1-4 haloalkyl, CN, OR a4 , SR a4 , C(O)N c4 R d4 , N c4 R d4 , NR c4 C(O)R b4 , NR c4 S(O)R b4 , NR c4 S(O) 2 R b4 , S(O)R b4 , S(O)NR c4 R d4 , S(O) 2 R b4 , and S(O) 2 N c4 R d4 ; wherein said C 1-4 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OR a4 , SR a4 , C(O)N c4 R d4 , N c4 R d4 , NR c4 C(O)R b4 , NR c4 S(O)R b4 , NR c4 S(O) 2 R b4 , S(O)R b4 , S(O)N c4 R d4 , S(O) 2 R b4 , and S(O) 2 NR c4 R d4 ;

R 6 , R 7 , and R 8 are each independently selected from H, halo, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 cyanoalkyl;

Cy 1 , Cy 2 , and Cy 3 are each independently selected from C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO 2 , OR a5 , SR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)OR a5 , OC(O)R b5 , OC(O)NR c5 R d5 , NR c5 R d5 , NR c5 C(O)R b5 , NR c5 C(O)OR a5 , NR c5 C(O)NR c5 R d5 , C(═NR e5 )R b5 , C(═NR e5 )NR c5 R d5 , NR c5 C(═NR e5 )NR c5 R d5 , NR c5 S(O)R b5 , NR c5 S(O) 2 R b5 , NR c5 S(O) 2 NR c5 R d5 , S(O)R b5 , S(O)NR c5 R d5 , S(O) 2 R b5 , and S(O) 2 NR c5 R d5 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C 1-4 haloalkyl, CN, NO 2 , OR a5 , SR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)OR a5 , OC(O)R b5 , OC(O)NR c5 R d5 , c(═NR e5 )NR c5 R d5 , NR c5 C(═NR e5 )NR c5 R d5 , NR c5 R d5 , NR c5 C(O)R b5 , NR c5 C(O)OR a5 , NR c5 C(O)NR c5 R d5 , NR c5 S(O)R b5 , NR c5 S(O) 2 R b5 , NR c5 S(O) 2 NR c5 R d5 , S(O)R b5 , S(O)NR c5 R d5 , S(O) 2 R b5 , and S(O) 2 NR c5 R d5 ;

each R a , R b , R c , R d , R a1 , R b1 , R c1 , R d1 , R a2 , R b2 , R c2 , R d2 , R a3 , R b3 , R c3 , R d3 , R a5 , R b5 , R c5 , and R d5 is independently selected from H, C 1-6 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl, C 3-10 cycloalkyl-C 1-4 alkyl, (5-10 membered heteroaryl)-C 1-4 alkyl, or (4-10 membered heterocycloalkyl)-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl, C 3-10 cycloalkyl-C 1-4 alkyl, (5-10 membered heteroaryl)-C 1-4 alkyl, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C 1-4 alkyl, C 1-4 haloalkyl, halo, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )N e6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)N e6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 N e6 R d6 , and S(O) 2 NR c6 R d6 ;

each R a4 , R b4 , R c4 , and R d4 is independently selected from H, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, and C 1-4 cyanoalkyl;

or any R c and R d together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, C 1-6 haloalkyl, halo, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 , wherein said C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 ;

or any R c1 and R d1 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C 1-6 alkyl, C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, C 1-6 haloalkyl, halo, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 , wherein said C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 ;

or any R c2 and R d2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, and 5-6 membered heteroaryl, C 1-6 haloalkyl, halo, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 , wherein said C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 ;

or any R c3 and R d3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, C 1-6 haloalkyl, halo, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 , wherein said C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O) OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 ;

or any R c5 and R d5 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, C 1-6 haloalkyl, halo, CN, OR′, SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 , wherein said C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 , NR c6 S(O) 2 NR c6 R d6 , and S(O) 2 NR c6 R d6 ;

each R a6 , R b6 , R c6 , and R d6 is independently selected from H, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, and C 2-4 alkynyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, and C 2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 haloalkyl, and C 1-4 haloalkoxy;

or any R c6 and R d6 together with the N atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 haloalkyl, and C 1-4 haloalkoxy; and

each R e , R e1 , R e2 , R e3 , R e5 , and R e6 is independently selected from H, C 1-4 alkyl, and CN;

n1 is 0, 1, 2, 3, 4, or 5;

n2 is 0, 1, or 2;

p is 0, 1, 2, or 3; and

q is 0, 1, 2, or 3.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

W is CR 6 ;

Y is N; and

Z is N.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

W is CR 6 ;

Y is N; and

Z is CR 8 .

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

W is CR 6 ;

Y is CR 7 ; and

Z is N.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

W is N;

Y is CR 7 ; and

Z is CR 8 .

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is absent.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is selected from C 2-6 alkenylene, C 3-6 heteroalkenylene, C 2-6 alkynylene, and C 3-6 heteroalkynylene, wherein said C 2-6 alkenylene, C 3-6 heteroalkenylene, C 2-6 alkynylene, and C 3-6 heteroalkynylene are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , ORB, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)OR a , NR c C(O)NR c R d , C(═NR e )R b , C(═NR e )NR c R d , NR c C(═NR e )NR c R d , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , S(O)R b , S(O)NR c R d , S(O) 2 R b , and S(O) 2 NR c R d .

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is selected from C 2-6 alkenylene and C 2-6 alkynylene, wherein said C 2-6 alkenylene and C 2-6 alkynylene are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , ORB, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 cyanoalkyl, C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R b , NR c C(O)OR a , NR c C(O)NR c R d , C(═NR e )R b , C(═NR e )NR c R d , NR c C(═NR e )NR c R d , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , S(O)R b , S(O)NR c R d , S(O) 2 R b , and S(O) 2 NR c R d .

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is selected from C 2-6 alkenylene and C 2-6 alkynylene.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is H.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 4 , and R 5 are each independently selected from halo, C 1-4 alkyl, C 1-4 halo alkyl, CN, and OR a4 .

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 4 , and R 5 are each independently selected from F, Cl, and methoxy.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 5 are each independently selected from F and Cl, and R 2 and R 4 are each methoxy.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 , R 7 , and R 8 are each independently selected from H and halo.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 , R 7 , and R 8 are each H.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is a group represented by Formula [aa].

17. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein Ring B is phenyl or pyridyl.

18. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein Ring C is a 5-membered carbocycle or a 5-membered heterocycle.

19. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein Ring C is a 6-membered carbocycle or a 6-membered heterocycle.

20. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein Formula [aa] is a structure selected from:

21. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein each R Y is independently selected from C 1-6 alkyl, Cy 1 , C(O)NR c1 R d1 C(O)OR a1 , and S(O) 2 R b1 , wherein said C 1-6 alkyl is optionally substituted with halo, OR a1 , NR c1 R d1 , Cy 1 .

22. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is a group represented by Formula [bb].

23. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein Q 1 , Q 2 , and Q 3 are each CH.

24. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein Q 1 is N and Q 2 , and Q 3 are each CH.

25. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein Q 1 and Q 2 are both CH and Q 3 is N.

26. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein each R A is independently selected from halo, C 1-6 alkyl, Cy 2 , and OR a2 ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R AZ .

27. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein n1 is 0, 1, or 2.

28. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is a group represented by Formula [cc].

29. The compound of claim 28 , or a pharmaceutically acceptable salt thereof, wherein A is a group represented by Formula [cc1]:

30. The compound of claim 28 , or a pharmaceutically acceptable salt thereof, wherein R B1 is C 1-6 alkyl optionally substituted with 1 or 2 substituents independently selected from R BZ .

31. The compound of claim 28 , or a pharmaceutically acceptable salt thereof, wherein each R BZ is independently selected from CN, OR a3 , and C(O)NR c3 R d3 .

32. The compound of claim 28 , or a pharmaceutically acceptable salt thereof, wherein n2 is 0.

33. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having Formula IIa, IIb, IIc, or IId:

wherein R′ and R 5 are independently selected from F and Cl.

34. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from:

5-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl-2,3-dihydro-1-benzofuran-2-carboxamide;

6-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethylchromane-2-carboxamide;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl-2,3-dihydro-1-benzofuran-2-carboxamide;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl-2,3-dihydro-1-benzofuran-2-carboxamide;

6-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethylchromane-2-carboxamide;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-{2-[(4-methylpiperazin-1-yl)carbonyl]-2,3-dihydro-1-benzofuran-5-yl}-1H-pyrazolo[3,4-d]pyrimidine;

6-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-3,4-dihydroisoquinolin-1(2H)-one;

6-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methyl-3,4-dihydroisoquinolin-1(2H)-one;

6-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-ethyl-3,4-dihydroisoquinolin-1(2H)-one;

6-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-isopropyl-3,4-dihydroisoquinolin-1(2H)-one;

6-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-3,4-dihydroisoquinolin-1(2H)-one;

6-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinoline;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[(4-methoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidine;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(trans-4-hydroxycyclohexyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(cis-4-hydroxycyclohexyl)isoindolin-1-one;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidine;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1H-pyrazolo[3,4-d]pyrimidine;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1H-pyrazolo[3,4-d]pyrimidine;

2-{4-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy}-N,N-dimethylethanamine;

2-Cyclopropyl-5-[6-(2,6-difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]isoindolin-1-one;

5-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(cis-4-hydroxycyclohexyl)isoindolin-1-one;

5-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(trans-4-hydroxycyclohexyl)isoindolin-1-one;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-{2-[(4-methylpiperazin-1-yl)carbonyl]-2,3-dihydro-1-benzofuran-5-yl}-1H-pyrazolo[4,3-c]pyridine;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrazolo[4,3-c]pyridine;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1H-pyrazolo[4,3-c]pyridine;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1H-pyrazolo[4,3-c]pyridine;

2-Cyclopropyl-5-[6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]isoindolin-1-one;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-methylphenoxy}-N,N-dimethylacetamide;

6-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2H-1,4-benzoxazin-3(4H)-one;

6-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-4-methyl-2H-1,4-benzoxazin-3 (4H)-one;

5-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-benzofuran-1(3H)-one;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}propanenitrile;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-fluorophenyl}-2-hydroxy-N,N-dimethylacetamide;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]phenoxy}-N,N-dimethylethanamine;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}-N-methylacetamide;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}-N,N-dimethylacetamide;

N-Cyclopropyl-2-{4-[6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}acetamide;

1-({4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}acetyl)azetidin-3-ol;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-[1-(2-morpholin-4-yl-2-oxoethyl)-1H-pyrazol-4-yl]-1H-pyrazolo[4,3-c]pyridine;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-{1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-pyrazol-4-yl}-1H-pyrazolo[4,3-c]pyridine;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}-N-(1-methylpiperidin-4-yl)acetamide;

1-({4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}acetyl)pyrrolidin-3-ol;

1-({4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}acetyl)-N,N-dimethylpyrrolidin-3-amine;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-{1-[2-(3-methoxypyrrolidin-1-yl)-2-oxoethyl]-1H-pyrazol-4-yl}-1H-pyrazolo[4,3-c]pyridine;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}-N-(2-methoxyethyl)acetamide;

1-({4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}acetyl)pyrrolidine-3-carbonitrile;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-(1-{2-[(3S)-3-fluoropyrrolidin-1-yl]-2-oxoethyl}-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-[(E)-2-(1-methyl-1H-pyrazol-4-yl)vinyl]-1H-pyrazolo[4,3-c]pyridine;

2-(4-{(E)-2-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]vinyl}-1H-pyrazol-1-yl)ethanol;

(2S)-1-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}propan-2-ol;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-ethylisoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-isopropylisoindolin-1-one;

2-Cyclopropyl-5-[6-(2,6-difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]isoindolin-1-one;

3-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-6-ethyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one;

6-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-3,4-dihydroisoquinolin-1(2H)-one;

6-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-N,N-dimethylchromane-2-carboxamide;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(2-methoxyethyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(tetrahydro-2H-pyran-4-yl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(cis-4-hydroxycyclohexyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trans-4-hydroxycyclohexyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(2-hydroxy-1-methylethyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(2-hydroxypropyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-6-fluoro-2-isopropylisoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(1-methylpiperidin-4-yl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[2-(dimethylamino)ethyl]isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[2-(1-methylpyrrolidin-2-yl)ethyl]isoindolin-1-one;

5-[6-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-ethylisoindolin-1-one;

6-(2,6-dichloro-3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridine;

3-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl]-1H-pyrazol-1-yl}propan-1-ol;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine;

2-{4-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-1H-pyrazol-1-yl}propanenitrile;

2-Cyclopropyl-5-[6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]isoindolin-1-one;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidine;

2-{4-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-1H-pyrazol-1-yl}propanenitrile;

3-[6-(2,6-Dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-6-ethyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-isopropylisoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(1-methylpiperidin-4-yl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-[2-(dimethylamino)ethyl]isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(2-hydroxy-1-methylethyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(2-hydroxypropyl)isoindolin-1-one;

5-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-N,N-dimethyl-2,3-dihydro-1-benzofuran-2-carboxamide;

7-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinoline;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-(2,3-dihydro-1-benzofuran-5-yl)-1H-pyrazolo[3,4-d]pyrimidine;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine;

2-{4-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1H-pyrazol-1-yl}ethanol;

5-[6-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-2-cyclopropylisoindolin-1-one;

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine;

Methyl 5-[6-(2,6-difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-1-benzofuran-2-carboxylate;

6-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-imidazo[1,2-a]pyridin-6-yl-1H-pyrazolo[3,4-d]pyrimidine; and

6-[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]quinolone.

35. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

36. A method of inhibiting an FGFR enzyme comprising contacting the FGFR enzyme with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

37. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

38. The method of claim 37 wherein said cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer. leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

39. A method of treating a myeloproliferative disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

40. The method of claim 39 wherein said myeloproliferative disorder is selected from polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).